PARP7-IN-27
PARP7-IN-27 is a blood-brain barrier-permeable and selective PARP7 inhibitor with an IC50 of 22.8 nM. PARP7-IN-27 alleviates neuroinflammation and astrocyte activation, mitigates autophagy-related alterations, reduces the levels of ischemia-associated pro-inflammatory factors, and maintains the expression of synaptic markers. PARP7-IN-27 can be used in studies related to ischemic stroke.
For research use only. We do not sell to patients.
- CAS No.: 3051563-45-9
- Formula: C15H11F4N3O2
- Molecular Weight:341.26
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
PARP7 22.8 nM (IC50) |
TNF-α |
IL-6 |
ULK1 |
In Vitro
PARP7-IN-27 (compound B-6) exhibits potent inhibitory activity against the PARP7 enzyme (IC50 = 22.8 nM), shows moderate selectivity for PARP10 (selectivity index = 4.7) and PARP14 (selectivity index = 5.3), and possesses higher selectivity for the remaining PARP family subtypes; it exerts a weak inhibitory effect on the hERG channel (IC50 = 27.45 μM)[1].
PARP7-IN-27 exhibits good Caco-2 cell permeability, with a Papp A-to-B value of 31.09 ×10-6 cm/s and an efflux ratio of 0.62[1].
PARP7-IN-27 (1‑4 μM) downregulates GFAP protein levels, reduces ULK1 expression, and decreases the LC3B‑II/LC3B‑I ratio in primary mouse astrocytes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | T1/2 | Tmax | Cmax | AUC0-∞ | Vz | CL | B/P |
|---|---|---|---|---|---|---|---|---|---|
| Mice[1] | 2 mg/kg | i.v. | 0.29 h | 0.08 h | 1963.08 ng/mL | 954.23 ng·h/mL | 901.07 mL/kg | 2122.64 mL/h/kg | 63.7 % |
In Vivo
PARP7-IN-27 (2.07 mg/kg; i.v.; single dose) retains substantial anti-ischemic activity when dosing is delayed up to 12 hours after ischemic onset in the rat tMCAO model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley rats (male, 180-200 g, transient middle cerebral artery occlusion ischemic stroke model)[1]
-
Dosage:0.69, 2.07, 6.21 mg/kg (24h acute infarct assessment)
2.07, 6.21 mg/kg (inflammatory evaluation)
2.07, 6.21 mg/kg (sensorimotor functional recovery) -
Administration:i.v. (single dose immediately post reperfusion) (acute infarct assessment)
i.v. (qd for 3 days starting 1 hour post reperfusion) (inflammatory evaluation)
i.v. (qd for 14 days starting 1 hour post reperfusion) -
Result:Reduced residual infarct volume to 9.00% at 0.69 mg/kg, 7.60% at 2.07 mg/kg, and 6.80% at 6.21 mg/kg, compared to 29.20% baseline infarct volume in the untreated model group.
Reduced Longa neurological deficit scores, decreased peri-infarct TNF-α and IL-6 levels, reduced elevated GFAP expression, and partially restored levels of synaptic markers PSD-95 and synaptophysin.
Reduced foot-fault ratio in the grid walking test, ameliorated forelimb use asymmetry in the cylinder test, shortened adhesive removal time, and improved striatal histopathological morphology over the 21-day observation period.
-
Animal Model:Sprague-Dawley rats (male, 180-200 g, transient middle cerebral artery occlusion ischemic stroke model)[1]
-
Dosage:2.07 mg/kg
-
Administration:i.v.; single dose administered immediately after reperfusion following 1, 3, 6, 12, or 18 hours of occlusion
-
Result:Retained robust neuroprotective effect at 6 hours post occlusion, clearly preserved anti-ischemic activity at 12 hours post occlusion, and showed reduced efficacy after 18 hours of occlusion.
Chemical Information
-
CAS No. 3051563-45-9
-
Molecular Weight 341.26
-
Formula C15H11F4N3O2
-
SMILES
O=C1C(C(F)(F)F)=C(N2CC(C(C3=CC=C(F)C=C3)=O)C2)C=NN1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Neurological Diseases
PINK1/Parkin-mediated mitophagy pathway is a mitochondrial quality-control signaling axis in which mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, activates Parkin recruitment and E3 ubiquitin ligase activity, promotes ubiquitination of outer mitochondrial membrane proteins, recruits selective autophagy adaptors, and drives lysosomal degradation of damaged mitochondria. In neurological disease research, this pathway is experimentally important because neurons, especially dopaminergic neurons, are highly dependent on mitochondrial integrity, and defective mitochondrial turnover can lead to mitochondrial dysfunction, oxidative stress, impaired neuronal survival, α-synuclein accumulation, and neuroinflammatory damage-associated signals. The genetic disease link is strongest in Parkinson’s disease because mutations in PRKN/parkin cause autosomal recessive juvenile parkinsonism, mutations in PINK1 cause hereditary early-onset Parkinson’s disease, and Drosophila studie
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)